PharmaNeuroBoost NV
http://www.pharmaneuroboost.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PharmaNeuroBoost NV
Antidepressants: Emerging From Their Funk?
Forest’s acquisition of Clinical Data to get its just-approved antidepressant signals continuing strong demand. But better, and much needed, treatments remain elusive. We profile four emerging antidepressant drug developers in this issue: Euthymics Biosciences, Naurex and PharmaNeuroBoost.
PharmaNeuroBoost NV
Belgian firm PharmaNeuroBoost NV creates NCEs out of existing therapeutics combined with the company’s proprietary boosting technology. The most advanced product in its pipeline, PNB01, is a combination of a low dose of pipamperone, a selective antagonist of the 5-HT2A and dopamine-4 receptors, with a fixed dose of the SSRI citalopram. It will soon embark on a Phase III pivotal trial comparing PNB01 with standard of care for treatment of major depressive disorder.
Recent Financings of Private Companies (12/2008)
Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
Recent Tech Transfer Deals (02/08)
Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- PNB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice